Higher fasting plasma insulin levels and reduced CSF-to-plasma insulin ratios, suggestive of insulin resistance, have been observed in patients with Alzheimer’s disease (AD) who do not possess an apolipoprotein E (APOE)-Ε4 allele. We examined the relationship of APOE and gender to peripheral insulin action and hyperinsulinemic memory facilitation in patients with AD using a sensitive measure of insulin-mediated glucose disposal. Participants were 32 patients with AD (9 without an Ε4 allele, 23 with an Ε4 allele) and 25 healthy age-matched adults (16 without an Ε4 allele, 9 with an Ε4 allele). AD subjects without an Ε4 allele had significantly lower insulin-mediated glucose disposal rates than AD patients with an Ε4 allele (p < 0.03), or than normal adults without an Ε4 allele (p < 0.02). Female AD subjects showed lower insulin-mediated glucose disposal rates than did male AD subjects (p < 0.02). No significant interaction was observed between APOE group and gender, suggesting that these effects are independent. AD subjects without an Ε4 allele also showed significant memory facilitation in the hyperinsulinemic condition (p < 0.04), whereas the AD-Ε4 group did not. Also in the hyperinsulinemic condition, AD patients without an Ε4 allele had lower insulin levels than patients with an Ε4 allele (p < 0.02), and women with AD had lower insulin levels than did men with AD despite similar insulin infusion rates and body mass (p < 0.004). No gender or genotype effects were observed in either condition for normal subjects. These results provide in vivo evidence of differences in insulin-mediated energy metabolism between Ε4 and non-Ε4 AD, and suggest that defective insulin action may be of particular pathophysiologic significance for patients without an Ε-4 allele.

Keywords:
Insulin, Alzheimer’s disease, Apolipoprotein E, Clinical neuroendocrinology
1.
Bauer J, Plaschke K, Martin E, Bardenheuer HJ, Hoyer S: Causes and consequences of neuronal energy deficit in sporadic Alzheimer’s disease. Ann NY Acad Sci 1997;826:379–381.
2.
Beal MF: Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357–366.
3.
Blass JP, Sheu KF, Piacentini S, Sorbi S: Inherent abnormalities in oxidative metabolism in Alzheimer’s disease: Interaction with vascular abnormalities. Ann NY Acad Sci 1997;826:382–385.
4.
Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr: Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998;50:164–168.
5.
Kamboh MI: Apolipoprotein E polymorphism and susceptibility to Alzheimer’s disease. Hum Biol 1995;67:195–215.
6.
Meyer C, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, Breitner JCS: APOE genotype predicts when – not whether – one is predisposed to develop Alzheimer’s disease. Nature Genet 1998;19:321–322.
7.
Bergman RN, Ider YZ, Bowden CR, Cobelli C: Quantitative estimation of insulin sensitivity. Am Physiol 1979;236:E667–E677.
8.
Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Turk A, Hoyer S, Zochling R, Boissl KW, Jellinger K, Riederer P: Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neural Transm 1998;105:423–438.
9.
Craft S, Newcomer J, Kanne S, Dagogo-Jack S, Cryer PE, Sheline Y, Luby J, Dagogo-Jack A, Alderson A: Memory improvement following induced hyperinsulinemia in Alzheimer’s disease. Neurobiol Aging 1996;17:123–130.
10.
Storandt M, Hill RD: Very mild senile dementia of the Alzheimer’s type II. Psychometric test performance. Arch Neurol 1989;46:383.
11.
Perret E: The left frontal lobe of man and the suppression of habitual responses in verbal categorical behavior. Neuropsychologia 1974;12:323–330.
12.
Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
13.
Emi M, Wu LL, Robertson MA, Myers RL, Hegele RA, Williams RR, White R, Lalouel JM: Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics 1988;3:373–379.
14.
Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 1990;31:545–548.
15.
Kuusisto J, Koivisto K, Mykkanen L, Helkala E-L, Vanhanen M, Hanninen T, Kervinen K, Kesaniemi YA, Riekkinen PJ, Laakso M: Association between features of the insulin resistance syndrome and Alzheimer’s disease independently of apolipoprotein E4 phenotype: Cross-sectional population based study. BMJ 1997;315:1045–1049.
16.
Ogbonna G, Theriault A, Adeli K: Hormonal regulation of human apolipoprotein E gene expression in HepG2 cells. Int J Biochem 1993;25:635–640.
17.
Descamps O, Billheimer D, Herz J: Insulin stimulates receptor-mediated uptake of apoE-enriched lipoproteins and activated a2-macroglobulin in adipocytes. J Biol Chem 1993;268:974–981.
18.
Rebeck WG, Harr SD, Strickland DK, Hyman BT: Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the α2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol 1995;37:211–217.
19.
Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK: LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995;82:331–340.
20.
Hong M, Lee V: Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997;272:19547–19553.
21.
Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong L-M, Jakes R, Huang DY, Pericak-Vance MA, Schmechel D, Roses AD: Isoform-specific interactions of apolipoprotein with microtubule-associated protein tau: Implications for Alzheimer disease. Proc Natl Acad Sci USA 1994;91:11183–11186.
22.
Lannert H, Hoyer S: Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 1998;112:1199–1208.
23.
Marfaing P, Penicaud L, Broer Y, Mraovitch S, Calando Y, Picon L: Effects of hyperinsulinemia on local cerebral insulin binding and glucose utilization in normoglycemic awake rats. Neurosci Lett 1990;115:279–285.
24.
Messier C, Destrade C: Insulin attentuates scopolamine-induced memory deficits. Psychobiology 1994;22:16–21.
25.
Kurochkin IV, Goto S: Alzheimer’s B-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 1994;345:33–37.
26.
McDermott JR, Gibson AM: Degradation of Alzheimer’s beta-amyloid protein by human and rat brain peptidases: Involvement of insulin-degrading enzyme. Neurochem Res 1997;22:49–56.
27.
Qiu WQ, Walsh DM, Ye Z, Konstantinos V, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ: Insulin-degrading enzyme regulates extracellular levels of amyloid B-protein by degradation. J Biol Chem 1998;273:32730–32738.
28.
Laakso M, Kuusisto J: Epidemiological evidence for the association of hyperglycaemia and atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Ann Med 1996;28:415–418.
29.
Lannert H, Wirtz P, Schuhmann V, Galmbacher R: Effects of estradiol (-17β) on learning, memory and cerebral energy metabolism in male rats after intracerebroventricular administration of streptozotocin. J Neural Transm 1998;105:1045–1063.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.